GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Glaxo (GSK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Glaxo (GSK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Glaxo beats both earnings and sales estimates in the third quarter of 2019.
AMETEK (AME) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
AMETEK's (AME) third-quarter results are expected to reflect benefits of growth strategies and acquisitions, and solid momentum across segments.
Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
by Zacks Equity Research
Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
Etsy (ETSY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Etsy's (ETSY) third-quarter results are likely to reflect strengthening product portfolio, mobile app and free shipping services.
Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.
Lattice (LSCC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lattice Semiconductor's (LSCC) third-quarter results are likely to reflect solid momentum across communications and computing, and industrial and automotive markets.
Waters (WAT) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) third-quarter 2019 results are likely to have benefited from solid momentum across pharma market, U.S. and China.
Universal Display (OLED) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Universal Display (OLED) third-quarter results are expected to have benefited from growing proliferation of OLED panels in ADAS, wearables, drones and AR/VR devices.
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
IPG Photonics (IPGP) to Report Q3 Earnings: What to Expect?
by Zacks Equity Research
Macroeconomic headwinds amid significant exposure to China are likely to have impacted IPG Photonics' (IPGP) third-quarter performance.
The Zacks Analyst Blog Highlights: Microsoft, Comcast, AT&T, Amgen and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Comcast, AT&T, Amgen and GlaxoSmithKline
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.
Can Merck (MRK) Keep the Earnings Beat Streak Alive in Q3?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven third-quarter sales. However, genericization of key drugs and increased competition are concerns.